Further, in vitro studies have shown that EGFR is abundantly expressed on oral cancer cells and that cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) is a crucial process associated with the therapeutic efficacy of cetuximab (27–29). Here, EGFR is linked to lip and oral cavity carcinoma.